Who Should Receive the Chemotherapy-Free Combination of Nivolumab Plus Ipilimumab as the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?
Ziming LiShun LuPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)